About ISOVive
ISOVive is a company based in Manassas (United States) founded in 2013 by Peter Swann and Jack Oswald. It operates as a D2C. ISOVive has raised $8.14 million across 1 funding round. ISOVive offers products and services including ISOVive Prebiotic Nectar. ISOVive operates in a competitive market with competitors including Sova Health, Infinant Health, rmdy, Ateria Health and G-NiiB, among others.
- Headquarter Manassas, United States
- Founders Peter Swann, Jack Oswald
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.14 M (USD)
in 1 rounds
-
Latest Funding Round
$8.14 M (USD), Series A
Oct 10, 2025
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ISOVive
ISOVive offers a comprehensive portfolio of products and services, including ISOVive Prebiotic Nectar. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Fermented prebiotic for balancing gut bacteria and relieving indigestion.
Funding Insights of ISOVive
ISOVive has successfully raised a total of $8.14M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.14 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $8.1M
-
First Round
First Round
(10 Oct 2025)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series A - ISOVive | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by ISOVive
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ISOVive
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Isovive Comparisons
Competitors of ISOVive
ISOVive operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sova Health, Infinant Health, rmdy, Ateria Health and G-NiiB, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Microbiome testing, consultations, and gut health supplements are offered.
|
|
| domain | founded_year | HQ Location |
Microbiome-based products to improve infant immune system
|
|
| domain | founded_year | HQ Location |
Developer of chewable tablets for improving digestion
|
|
| domain | founded_year | HQ Location |
Food supplements for gut health are developed by Ateria Health.
|
|
| domain | founded_year | HQ Location |
Develops innovative microbiome-based technologies for disease diagnostics and treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Isovive
Frequently Asked Questions about ISOVive
When was ISOVive founded?
ISOVive was founded in 2013 and raised its 1st funding round 12 years after it was founded.
Where is ISOVive located?
ISOVive is headquartered in Manassas, United States. It is registered at Manassas, Virginia, United States.
Who is the current CEO of ISOVive?
Jack Oswald is the current CEO of ISOVive. They have also founded this company.
Is ISOVive a funded company?
ISOVive is a funded company, having raised a total of $8.14M across 1 funding round to date. The company's 1st funding round was a Series A of $8.14M, raised on Oct 10, 2025.
What does ISOVive do?
ISOVive is a naturally fermented prebiotic nectar supplement that supports digestive health by balancing gut bacteria and providing relief from heartburn and indigestion. It works by feeding beneficial microbes with its unique MIMO prebiotic, addressing microbiome imbalances caused by modern diets. Based in Manassas, VA, USA, the company offers online sales with a 30-day money-back guarantee and is backed by scientific research and medical experts.
Who are the top competitors of ISOVive?
ISOVive's top competitors include Sova Health, Infinant Health and rmdy.
What products or services does ISOVive offer?
ISOVive offers ISOVive Prebiotic Nectar.